Von Hippel-Lindau Syndrome: New Awareness Campaign and Treatment Advances for Rare Genetic Disease

• Von Hippel-Lindau syndrome is a rare genetic condition affecting approximately one in 53,000 people and predisposing them to multiple benign and malignant tumors.
• The newly presented awareness campaign, titled “Oltre le pieghe della rarità,” highlights patient experiences through personal stories, origami artwork, and an information portal.
• Recent therapeutic developments include the Italian Medicines Agency approval of the medication belzutifan (Welireg).

Manifestations vary widely even within the same family, potentially affecting the kidneys, pancreas, retina, brain, and spinal cord.

Benign tumors can still inflict severe damage by impairing vision or compressing nervous structures, making structured surveillance essential before complications arise.

The diagnostic pathway typically incorporates genetic counseling, eye examinations, blood and urine tests, and magnetic resonance imaging tailored to the patient’s age and affected organs.

“Ricevere una diagnosi di Vhl significa vedere cambiare all’improvviso il modo di immaginare il proprio futuro. Vuol dire convivere con domande, paure e controlli continui, spesso condividendo questo percorso con altri membri della propria famiglia, e cercare ogni giorno di non lasciare che la malattia occupi tutto lo spazio della propria vita,” said Francesco Lombardi, presidente dell’Associazione Italiana Famiglie VHL Onlus, as reported by ANSA.

New Treatments Expand Clinical Options Through Multidisciplinary Care

Alongside routine surveillance and surgical procedures, new treatments have expanded clinical options for people managing the condition.

Treatment decisions require specialist evaluation within a continuum of coordinated multidisciplinary care.

MSD and Associazione Italiana Famiglie VHL Onlus Promote Awareness

The awareness initiative promoted by MSD with the patronage of the Associazione Italiana Famiglie VHL Onlus seeks to shed light on an ultra-rare multisystemic disease.

Costa emphasized strengthening territorial networks and ensuring homogeneous care pathways.

“Ancora una volta, abbiamo scelto un modo nuovo e insolito per raccontare la malattia, andando oltre il linguaggio clinico e mettendo al centro i pazienti,” said Nicoletta Luppi, presidente e amministratrice delegata di MSD Italia, highlighting the importance of early access to innovations and continued investment in biomedical research.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.